Novo Nordisk enlists two Flagship biotechs to develop obesity, MASH drugs

Novo Nordisk may already have one blockbuster obesity drug in its portfolio, but the Danish drugmaker has actively begun searching out others, including through a new partnership announced Thursday.

Novo Nordisk will work with Omega Therapeutics, a startup founded by venture creation firm Flagship Pioneering, to develop an mRNA treatment for obesity. The pharmaceutical company said Thursday that it has also signed a deal with Flagship-founded startup Cellarity to develop a new medicine for the fatty liver disease MASH, formerly known as NASH.

These are the first two deals announced under a collaboration agreement Flagship and Novo Nordisk struck in 2022.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Already have an account? Log in

Individual plans

Group plans

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe

Log In